Verona Pharma’s investigational agent RPL554 will be named ensifentrine, the company announced. The “-fentrine” stem in the International Nonproprietary Names (INN) Programme indicates recognition from the World Health Organization (WHO) that RPL554 inhibits multiple phosphodiesterases. Ensifentrine is being developed for the maintenance treatment of chronic obstructive pulmonary disease (COPD)…
News
The ProAir Digihaler, a digital inhaler that allows patients with asthma and chronic obstructive pulmonary disease (COPD) to track their inhaler usage through a mobile app, has been approved by the U.S. Food and Drug Administration (FDA), its developer Teva Pharmaceuticals announced. The albuterol inhaler (albuterol sulfate, 117 micrograms)…
Bevespi Aerosphere (glycopyrronium/formoterol fumarate), a therapy developed by AstraZeneca, has been approved by the European Commission as a maintenance treatment for adults with chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere is a combination of two bronchodilators (glycopyrronium and formoterol fumarate) delivered twice daily in a fixed dose…
The U.S. Food and Drug Administration has approved Olympus‘ Spiration Valve System (SVS) as a minimally invasive treatment for severe emphysema, a progressive form of chronic obstructive pulmonary disease (COPD). The approval is based on positive results from the EMPROVE clinical trial (NCT01812447), which showed meaningful improvements in…
A Phase 2 clinical trial is enrolling participants to evaluate the safety and efficacy of Verona Pharma’s dry powder inhaler RPL554 as a potential maintenance treatment for people with moderate to severe chronic obstructive pulmonary disease (COPD). RPL554 is a dual inhibitor of the proteins phosphodiesterase (PDE) 3 and…
Chronic obstructive pulmonary disease (COPD) is much more common in obese individuals ages 50 and older who have never smoked, according to a study that also shows that the odds of having COPD increases with the level of obesity. Led by researchers at the University of Toronto in Canada, the…
Very few patients with chronic obstructive pulmonary disease (COPD) start pulmonary rehabilitation after being hospitalized, despite its proven benefits and clinical guidelines recommending it shortly after discharge, a study shows. Study results were published in the journal Annals of the American Thoracic Society, in an article titled “…
Two new studies highlight the important role of mucus in cleaning and protecting the lungs, and how its accumulation and impaired clearance can contribute to the worsening of lung diseases such as chronic obstructive pulmonary disease (COPD). In the studies, researchers show how mucus in the lungs forms a protective…
Health technology company Royal Philips is launching a global initiative on World COPD Day Wednesday in hopes of raising awareness of chronic obstructive pulmonary disease (COPD) and encouraging patients to remain active and improve their overall quality of life. COPD is a progressive disorder estimated to affect more than 251…
Theravance Biopharma and Mylan announced that the U.S. Food and Drug Administration (FDA) approved their New Drug Application (NDA) for revefenacin (TD-4208) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The therapy will be marketed as an inhalation solution with the brand name Yupelri. The…
Recent Posts
- What a chemistry professor’s stinky plant taught me about COPD
- Oxygen tubing brings me breath, clarity, and independence
- Erasing the stigma of supplemental oxygen so that we can breathe again
- New nebulized combo therapy rapidly boosts lung function in COPD
- I’m going forward, but I don’t need to break the sound barrier to be heard